Statins and statin combinations for high cholesterolReferencesCitations Gami A (2007). Secondary prevention of ischaemic
cardiac events, search date July 2004. Online version of BMJ Clinical Evidence. Also available online:
http://www.clinicalevidence.com. Cannon CP, et al. (2004). Intensive versus moderate
lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350(15): 1495–1504. Nissen SE, et al. (2004). Effect of intensive compared
with moderate lipid-lowering therapy on progression of coronary
atherosclerosis. JAMA, 291(9): 1071–1080. Grundy SM, et al. (2004). Implications of recent
clinical trials of the National Cholesterol Education Program Adult Treatment
Panel III Guidelines. Circulation, 110(2): 227–239.
[Erratum in Circulation, 110(6): 763.] Grundy SM, et al. (2001). Executive summary of the
third report of the National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III). JAMA, 285(19):
2486–2497. Nissen SE, et al. (2005). Statin therapy, LDL
cholesterol, C-reactive protein, and coronary artery disease. New England Journal of Medicine, 352(1): 29–38. Ridker PM, et al. (2005). C-reactive protein levels
and outcomes after statin therapy. New England Journal of Medicine, 352(1): 20–28. Pasternak RC, et al. (2002). ACC/AHA/NHLBI advisory on
the use and safety of statins. Circulation, 106(8):
1024–1028. Grundy SM (2001). United States cholesterol guidelines
2001: Expanded scope of intensive low-density lipoprotein-lowering therapy.
American Journal of Cardiology, 88(7B): 23J–27J.
Sacks FM (2001). The relative role of low-density
lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary
artery disease: Evidence from large-scale statin and fibrate trials.
American Journal of Cardiology, 88(12A): 14N–18N.
| |